| Date | Title | Description |
| 28.03.2023 | Biomea Fusion Announces Positive Data from Initial Cohorts o... | Redwood City, CA — March 28, 2023 — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage ... |
| 06.03.2023 | BridgeBio Announces Positive Phase 2 Cohort 5 Results of Inf... | Palo Alto, CA — March 06, 2023 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-sta... |
| 09.02.2023 | Spruce Biosciences Announces $53.6 Million Private Placement... | South San Francisco, CA — Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical co... |
| 07.02.2023 | Garuda Therapeutics Secures $62 Million Series B Financing t... | CAMBRIDGE, MA.– Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem c... |
| 05.01.2023 | Spruce Biosciences and Kaken Pharmaceutical Announce Strateg... | San Francisco, CA & TOKYO – Jan 5, 2023 – Spruce Biosciences, Inc. (Nasdaq: SPRB) and Kaken Phar... |
| 20.12.2022 | Verona Pharma Announces Ensifentrine Meets Primary and Key S... | LONDON and RALEIGH, NC – December 20, 2022 – Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or th... |
| 14.12.2022 | Syndax Announces Closing of Public Offering of Common Stock ... | Waltham, MA — December 14, 2022 — Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Na... |
| 05.12.2022 | Syndax Announces U.S. FDA Breakthrough Therapy Designation G... | WALTHAM, MA – December 5, 2022 – Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage bioph... |
| 01.11.2022 | Monte Rosa Therapeutics Announces First Patient Dosed in Pha... | BOSTON, MA — November 1, 2022 — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology compan... |
| 31.10.2022 | Biomea Fusion Announces Dosing of First Patient with Type 2 ... | REDWOOD CITY, CA – Oct. 31, 2022 — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage b... |
| 17.10.2022 | Treeline Biosciences - An Update From Our Founders | October 17, 2022
“Homo sapiens is a storytelling animal that thinks in stories rather than in numbe... |
| 27.09.2022 | Forge Biologics Fuels Gene Therapy Manufacturing Engine with... | COLUMBUS, OH — September 27, 2022 — Forge Biologics, a gene therapy-focused contract development and... |
| 12.09.2022 | Forge Biologics Announces $90 Million Series C Financing to ... | • Total capital raised of $330 million since the Company’s launch in 2020
• Financing expands plann... |
| 15.08.2022 | Verona Pharma plc Announces Closing of Upsized Underwritten ... | LONDON and RALEIGH, NC — August 15, 2022 — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the ... |
| 09.08.2022 | Verona Pharma Announces Ensifentrine Meets Primary Endpoint ... | LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona... |
| 03.08.2022 | Poseida Therapeutics Announces Strategic Global Collaboratio... | Leveraging Poseida’s novel approach to cell therapy and Roche’s expertise in developing and commerci... |
| 28.07.2022 | Elevation Oncology Expands Pipeline through Exclusive Licens... | Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYS... |
| 27.07.2022 | Cidara Therapeutics Submits NDA for Rezafungin and Announces... | Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 202... |
| 14.06.2022 | Dren Bio Announces $65 Million Series B Financing to Advance... | – Momentum continues to build for Dren Bio after successfully forming highly experienced senior lead... |
| 13.06.2022 | BridgeBio Pharma Shares Positive Phase 2b Data and Announces... | -Treatment with encaleret resulted in rapid and sustained restoration of normal mineral homeostasis,... |
| 13.05.2022 | BridgeBio Pharma Sells Rare Pediatric Disease Priority Revie... | –Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV... |
| 05.04.2022 | Atreca Announces Expansion of Preclinical Pipeline | Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) a... |
| 03.04.2022 | BridgeBio Pharma Presents Updated Results from Phase 2 Open-... | PALO ALTO, CA – April 3, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”)... |
| 31.03.2022 | CIDARA THERAPEUTICS ANNOUNCES THE COMPLETION OF DOSING THE F... | SAN DIEGO, CA – March 31, 2022 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company d... |
| 30.03.2022 | Antios Therapeutics’ ATI-2173 Demonstrates Suppression of He... | DOYLESTOWN, PA – March 30, 2022 – Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceut... |
| 29.03.2022 | Prolacta - Independent, head-to-head study shows significant... | DUARTE, CA- March 29, 2022 – An independent, head-to-head study from Neuburg, Germany, shows extreme... |
| 25.03.2022 | ADMA Biologics Announces FDA Approval of Extended Shelf Life... | RAMSEY, NJ and BOCA RATON, FL – March 25, 2022 — ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an en... |
| 24.03.2022 | ADMA Biologics Announces Fourth Quarter and Full Year 2021 F... | RAMSEY, NJ and BOCA RATON, FL – March 24, 2022 — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the ... |
| 22.03.2022 | ObsEva Announces Additional Efficacy Results for Linzagolix ... | GENEVA, Switzerland – March 22, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical comp... |
| 17.03.2022 | AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financia... | CAMBRIDGE, MA.- March 17, 2022– AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy ... |
| 15.03.2022 | Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU... | ST. LOUIS, MO and SAN DIEGO, CA – March 15, 2022 – Wugen, Inc., a clinical-stage biotechnology compa... |
| 14.03.2022 | Elevation Oncology Appoints David Dornan, Ph.D., as Chief Sc... | NEW YORK, NY – March 14, 2022 — Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical-stage biopharmac... |
| 14.03.2022 | BridgeBio Pharma Announces Positive Phase 2 Data for Limb-gi... | PALO ALTO, CA – March 14, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”... |
| 14.03.2022 | James Brady Joins Verona Pharma as Non-Executive Director | LONDON and RALEIGH, NC – March 14, 2022 — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clin... |
| 08.03.2022 | BridgeBio Pharma and Sentynl Therapeutics Announce Asset Pur... | Palo Alto and Solana Beach, CA – March 8, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), ... |
| 07.03.2022 | ADMA BioCenters Receives FDA Approval for its Fifth Plasma C... | RAMSEY, NJ and BOCA RATON, FL and CONYERS, GA – March 07, 2022 — ADMA Biologics, Inc. (NASDAQ: ADMA)... |
| 03.03.2022 | Atreca Reports Fourth Quarter and Full-Year 2021 Financial R... | SAN CARLOS, CA – March 03, 2022 — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnolo... |
| 03.03.2022 | Helsinn Group and BridgeBio Pharma Announce Update to Strate... | Lugano, Switzerland and Palo Alto, CA – March 3, 2022 — Helsinn Group (Helsinn), a fully integrated,... |
| 28.02.2022 | Nuvation Bio Reports Fourth Quarter and Full Year 2021 Finan... | NEW YORK, NY – February 28, 2022 – Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackl... |
| 23.02.2022 | Poseida Therapeutics Hosts Second Annual Virtual R&D Day... | SAN DIEGO, CA – February 23, 2022 — Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biop... |
| 16.02.2022 | MARKER THERAPEUTICS ANNOUNCES CLINICAL PROGRAM UPDATES AND P... | HOUSTON, TX – February, 16, 2022 — Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-... |
| 14.02.2022 | CIDARA THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF ITS INVESTIG... | SAN DIEGO, CA – February 14, 2022 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology compan... |
| 10.02.2022 | ObsEva Enters into Licensing Agreement with Theramex for the... | GENEVA, Switzerland – February 10, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical c... |
| 09.02.2022 | AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial o... | CAMBRIDGE, MA – February 9, 2022 — AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene thera... |
| 08.02.2022 | Zosano Pharma Announces Pricing of $15.4 Million Public Offe... | FREMONT, CA- February 08, 2022 — Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharma... |
| 01.02.2022 | AVROBIO Announces the Appointment of Sean O’Bryan as Chief R... | CAMBRIDGE, MA – February 1, 2022 — AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene thera... |
| 31.01.2022 | Viracta Therapeutics Announces First Patient Dosed in Phase ... | SAN DIEGO, CA – January 31, 2022 — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology c... |
| 27.01.2022 | BridgeBio Pharma Announces Dosing of First Patient in Phase ... | PALO ALTO, CA – January 27, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Compan... |
| 25.01.2022 | Biomea Fusion Announces First Patient Dosed | REDWOOD CITY, CA – January 25, 2022 – Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), today announced... |
| 25.01.2022 | Monte Rosa Therapeutics and Yeda, the commercial arm of the ... | BOSTON, MA and REHOVOT, Israel – January 25, 2022 — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a ... |
| 24.01.2022 | Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Tria... | LONDON and RALEIGH, NC – January 24, 2022 — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the... |
| 20.01.2022 | Nuvation Bio Announces FDA Clearance of Investigational New ... | NEW YORK, NY – January 20, 2022 — Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackli... |
| 19.01.2022 | MARKER THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR... | HOUSTON, TX – January 19, 2022 — MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-on... |
| 18.01.2022 | ADMA BioCenters Receives FDA Approval for its Fourth Plasma ... | RAMSEY, NJ, BOCA RATON, FL and GOOSE CREEK, SC – January 18, 2022 — ADMA Biologics, Inc. (NASDAQ: AD... |
| 13.01.2022 | BridgeBio Announces Clinical Collaboration with Amgen to Stu... | PALO ALTO, CA – January 13, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-s... |
| 10.01.2022 | Nabriva Therapeutics Provides Business Update and Announces ... | DUBLIN, Ireland and FORT WASHINGTON, PA – January 10, 2022 (GLOBE NEWSWIRE) — Nabriva Therapeutics p... |
| 06.01.2022 | Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Dia... | REDWOOD CITY, CA – January 6, 2022 – Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage... |
| 06.01.2022 | ObsEva Announces Positive Topline Results for Linzagolix 200... | GENEVA, Switzerland – January 6, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical com... |
| 05.01.2022 | Zosano Pharma Announces Publication of Clinical Data Demonst... | FREMONT, CA – January 05, 2022 — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharma... |
| 05.01.2022 | Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subs... | LONDON and RALEIGH, NC – January 05, 2022 — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the... |
| 04.01.2022 | AVROBIO Reprioritizes Pipeline Programs | CAMBRIDGE, MA – January 4, 2022 — AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therap... |
| 03.01.2022 | Novo Holdings to acquire Medical Knowledge Group | Denmark – January 03, 2022 – Novo Holdings A/S (“Novo Holdings”), a leading global life sciences inv... |
| 27.12.2021 | BridgeBio Pharma Reports Month 12 Topline Results from Phase... | PALO ALTO, CA – December 27, 2021 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced topline re... |
| 21.12.2021 | ARMGO Pharma raises $35 million to progress clinical studies... | Ardsley, NY – December 20, 2021 – ARMGO Pharma Inc (“ARMGO”), a leading novel small molecule therape... |
| 20.12.2021 | Poseida Therapeutics Announces FDA Clearance of Investigatio... | SAN DIEGO, CA – December 20, 2021 — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biop... |
| 20.12.2021 | ObsEva Added to the NASDAQ Biotechnology Index | GENEVA, Switzerland – December 20, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical c... |
| 17.12.2021 | Harmony Biosciences to be Added to the Nasdaq Biotech Index | PLYMOUTH MEETING, PA – December 17, 2021– Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HR... |
| 16.12.2021 | Viracta Therapeutics to be Added to the Nasdaq Biotechnology... | SAN DIEGO, CA – December 16, 2021 — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology ... |
| 15.12.2021 | Nuvation Bio Receives FDA Fast Track Designation for NUV-422... | NEW YORK, NY – December 15, 2021 — Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackl... |
| 14.12.2021 | ews Antios Therapeutics and Arbutus Biopharma Announce First... | MENDHAM, NJ and WARMINSTER, PA – December 14, 2021 – Antios Therapeutics, Inc. (“Antios”) and Arbutu... |
| 14.12.2021 | Antios Therapeutics and Arbutus Biopharma Announce First Pat... | MENDHAM, NJ and WARMINSTER, PA – December 14, 2021 – Antios Therapeutics, Inc. (“Antios”) and Arbutu... |
| 13.12.2021 | Nuvation Bio Announces FDA Clearance of Investigational New ... | NEW YORK, NY – Dec. 13, 2021 — Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling ... |
| 11.12.2021 | Syndax Pharmaceuticals Announces Updated Positive Data Demon... | WALTHAM, MA – December 11, 2021 — Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Na... |
| 09.12.2021 | Syndax Pharmaceuticals Announces Closing of Global Collabora... | WALTHAM, MA – December 09, 2021 — Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that t... |
| 08.12.2021 | Nuvation Bio Announces FDA Clearance of Investigational New ... | NEW YORK, NY – Dec. 8, 2021– Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling so... |
| 06.12.2021 | Aeglea BioTherapeutics Announces Achievement of Primary Endp... | AUSTIN, TX – December 6, 2020 — Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotec... |
| 01.12.2021 | Prolacta Bioscience enrolls first infant in Japan-based clin... | DUARTE, CA – Dec. 01, 2021 — Prolacta Bioscience®, the world’s leading hospital provider of 100% hum... |
| 23.11.2021 | Talaris Therapeutics Announces Initiation of Phase 2 Clinica... | BOSTON, MA and LOUISVILLE, KY – November 30, 2021 – Talaris Therapeutics, Inc., (Nasdaq: TALS), a la... |
| 22.11.2021 | Prolacta Bioscience Appoints Dr. Anne Beal to Board of Direc... | DUARTE, CA – November 22, 2021 — Prolacta Bioscience®, the world’s leading hospital provider of 100%... |
| 22.11.2021 | Obseva Announces U.S. FDA Acceptance of New Drug Application... | FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterin... |
| 19.11.2021 | BridgeBio Pharma and Helsinn Group Announce Strategic Collab... | Palo Alto, CA, and Lugano, Switzerland – November 19, 2021 – BridgeBio Pharma, Inc. (Nasdaq: BBIO), ... |
| 15.11.2021 | ews Antios Therapeutics Announces Agreement with IRBM, INGM ... | MENDHAM, NJ and ROME, ITALY – November 15, 2021 – Antios Therapeutics, Inc. (“Antios”), a clinical-s... |
| 10.11.2021 | Monte Rosa Therapeutics Announces First Development Candidat... | BOSTON, MA – November 10, 2021 — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology compa... |
| 03.11.2021 | Antios Therapeutics Raises $75 Million in a Series B-1 Fundi... | MENDHAM, NJ – November 03, 2021 — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmace... |
| 29.10.2021 | Prolacta Bioscience Develops World’s First Test to Directly ... | DUARTE, CA – October 29, 2021 – Prolacta Bioscience®, the world’s leading hospital provider of 100% ... |
| 21.10.2021 | Harmony Biosciences to be Added to the S&P SmallCap 600®... | PLYMOUTH MEETING, PA – Oct. 21, 2021 – Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY)(“Harmony” o... |
| 12.10.2021 | Poseida Therapeutics Announces Research Collaboration with T... | Collaboration to leverage Poseida’s non-viral piggyBac® DNA Modification System, Cas-CLOVER™ Site-Sp... |
| 27.09.2021 | Syndax Pharmaceuticals and Incyte Announce Global Collaborat... | Syndax to receive $ 152 million in cash ($117 million upfront plus a $35 million equity investment, ... |
| 23.09.2021 | Garuda Therapeutics Launches with $72 Million Series A Finan... | CAMBRIDGE, MA – September 23, 2021 – Garuda Therapeutics, a company creating off-the-shelf, durable ... |
| 27.07.2021 | BridgeBio Announces Clinical Collaboration With Bristol Myer... | First clinical combination study set to evaluate safety and preliminary efficacy in non-small cell l... |
| 15.07.2021 | Wugen Raises $172 Million to Advance Clinical Stage Memory N... | Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate stud... |
| 29.06.2021 | Reneo Pharmaceuticals Added to the Russell 2000® and Russell... | SAN DIEGO, CA – June 29, 2021 – Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmac... |
| 24.06.2021 | Elevation Oncology Announces Pricing of Initial Public Offer... | NEW YORK, NY – June 24, 2021 – Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmace... |
| 23.06.2021 | Monte Rosa Therapeutics Announces Pricing of Initial Public ... | Boston, MA – June 23, 2021 – Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company d... |
| 10.06.2021 | Verona Pharma and Nuance Pharma Announce $219 Million Strate... | $40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent c... |
| 08.06.2021 | Aclaris Therapeutics Announces Positive Preliminary Topline ... | TI-1777 Achieved Statistically Significant Result in the Primary Efficacy Endpoint at Week 4
Minimal... |
| 28.05.2021 | BridgeBio Pharma’s Affiliate QED Therapeutics And Partner He... | Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) a... |
| 14.05.2021 | BridgeBio Pharma Receives FDA Fast Track Designation For Inv... | Preclinical Data for Congenital Adrenal Hyperplasia and Canavan Disease Programs Shared at American ... |
| 11.05.2021 | Talaris Therapeutics Announces Closing of Initial Public Off... | BOSTON and LOUISVILLE, KY – May 11, 2021 – Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinica... |
| 20.04.2021 | Biomea Announces Closing of Initial Public Offering | REDWOOD CITY, CA – April 20, 2021 – Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-sta... |